title: The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction.
abstract: OBJECTIVE
  This prospective study was designed to evaluate the potential protective effect of nebivolol compared with metoprolol on the development of contrast-induced nephropathy (CIN) following coronary angiography in patients with renal dysfunction.
  
  
  METHODS
  Ninety patients with stable coronary angina pectoris with renal insufficiency (creatinine value ≥1.2 mg/dl) were included for this prospective study. Patients were divided into two groups. Patients in group 1 (n=55) received oral administration of nebivolol 5 mg/daily for coronary artery disease and/or hypertension. Group 2 consisted of 35 patients who received metoprolol 50 mg/daily for the same indications. All patients were hydrated with 0.9% NaCl at a rate of 1 mL/kg/hr for 12 hours before and 24 hours after the procedure. Patients were also given N-acetylcysteine (NAC) 600 mg twice a day, beginning 24 hours before and continuing 48 hours after the procedure. All patients underwent routine coronary angiography. Serum creatinine was assessed just before, immediately after and 48 hours after the procedure. CIN was defined as an increase in serum creatinine concentration of ≥25% within 48 hours after the procedure compared to the patient's baseline value. Tests for significance between groups were conducted using the independent sample t-test for continuous variables and Chi-square test for categorical variables.
  
  
  RESULTS
  Baseline serum creatinine levels were statistically comparable in two groups. Following angiography, serum creatinine levels increased in both groups. Post-angiographic creatinine levels were not statistically different in the nebivolol and the metoprolol groups. Contrast induced nephropathy developed in 13 patients (24%) of the nebivolol group and in 12 patients (33%) of the metoprolol group. The incidence of CIN was statistically significantly lower in the nebivolol group comparing with the metoprolol group (p=0.03).
  
  
  CONCLUSIONS
  The use of oral nebivolol for one week at a dose of 5 mg per day may decrease the incidence of contrast-induced nephropathy in patients who underwent coronary angiography with renal dysfunction. The small numbers of this study do not allow to draw final conclusion on the use of nebivolol in the prevention of CIN. Therefore, larger studies may be necessary to address the definite role of nebivolol in this setting.
authors.affiliation: Clinic of Cardiology, Atatürk Training and Research Hospital, İzmir-Turkey.
authors.forename: Eyüp
authors.initials: E
authors.lastname: Avci
authors.forename: Murat
authors.initials: M
authors.lastname: Yeşil
authors.forename: Serdar
authors.initials: S
authors.lastname: Bayata
authors.forename: Nursen
authors.initials: N
authors.lastname: Postaci
authors.forename: Erdinç
authors.initials: E
authors.lastname: Arikan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cirit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001578:Benzopyrans / Q000008:administration & dosage*; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging*; D003404:Creatinine / Q000097:blood; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000150:complications; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage; D008875:Middle Aged; D000068577:Nebivolol; D011446:Prospective Studies; D020011:Protective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D001578:Benzopyrans; D003287:Contrast Media; D004983:Ethanolamines; D020011:Protective Agents; D014665:Vasodilator Agents; D000068577:Nebivolol; D003404:Creatinine; D008790:Metoprolol